Coya Therapeutics, Inc. Common Stock (COYA)vsInsmed Inc (INSM)
COYA
Coya Therapeutics, Inc. Common Stock
$4.20
+1.08%
HEALTHCARE · Cap: $98.75M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 7532% more annual revenue ($606.42M vs $7.95M). INSM leads profitability with a -2.1% profit margin vs -2.7%. INSM earns a higher WallStSmart Score of 39/100 (F).
COYA
Avoid29
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 2027.7% year-over-year
Safe zone — low bankruptcy risk
Reasonable price relative to book value
No standout strengths identified
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -51.4% — below average capital efficiency
Negative free cash flow — burning cash
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : COYA
The strongest argument for COYA centers on Revenue Growth, Altman Z-Score, Price/Book. Revenue growth of 2027.7% demonstrates continued momentum.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : COYA
The primary concerns for COYA are EPS Growth, Market Cap, Return on Equity.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
COYA profiles as a hypergrowth stock while INSM is a turnaround play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
COYA is growing revenue faster at 2027.7% — sustainability is the question.
COYA generates stronger free cash flow (-1M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 29/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Coya Therapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company is headquartered in Houston, Texas.
Visit Website →Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?